Intravitreal Aflibercept for Diabetic Macular Edema

Brown, David M.; Schmidt‐Erfurth, Ursula; Diana, V.; Holz, Frank G.; Boyer, David S.; Midena, Edoardo; Heier, Jeffrey S.; Terasaki, Hiroko; Kaiser, Peter K.; Marcus, Dennis M.; Nguyen, Quan Dong; Jaffe, Glenn J.; Slakter, Jason S.; Simader, Christian; Soo, Yuhwen; Schmelter, Thomas; Yancopouloš, George D.; Stahl, Neil; Vitti, Robert; Berliner, Alyson J.; Zeitz, Oliver; Metzig, Carola; Korobelnik, J.-F.

doi:10.1016/j.ophtha.2015.06.017

Cited by 471 publications

(268 citation statements)

References 27 publications

Supporting

Mentioning

246

Contrasting

Unclassified

Order By: Relevance

“…In the US, less than 50% of the patients with diabetes receive an annual DR examination 4–8 . Many of those with vision-threatening diabetic retinopathy (VTDR) 9 are not diagnosed in time to benefit from the remarkable efficacy of DR therapy established by the Diabetic Retinopathy Study (DRS) 10 , Early Treatment Diabetic Retinopathy Study (ETDRS) 11, 12 and clinical trials of intravitreal anti-VEGF therapy 13–15 . VTDR is defined as severe non-proliferative or proliferative DR, with or without clinically significant macular edema (CSME) 2, 9 .…”

Section: Introductionmentioning

confidence: 99%

A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy

Maa

Feuer

Davis

et al. 2016

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Aims To evaluate the performance of the RETeval device, a handheld instrument using flicker electroretinography (ERG) and pupillography on undilated subjects with diabetes, to detect vision-threatening diabetic retinopathy (VTDR). Methods Performance was measured using a cross-sectional, single armed, non-interventional, multi-site study with Early Treatment Diabetic Retinopathy Study 7-standard field, stereo, color fundus photography as the gold standard. The 468 subjects were randomized to a calibration phase (80%), whose ERG and pupillary waveforms were used to formulate an equation correlating with the presence of VTDR, and a validation phase (20%), used to independently validate that equation. The primary outcome was the prevalence-corrected area under the receiver operating characteristic (ROC) curve for the detection of VTDR. Results The area under the ROC curve was 0.86 for VTDR; with sensitivity of 83%, specificity was 78% and negative predictive value was 99%. The average testing time was 2.3 minutes. Conclusions With a VTDR prevalence similar to that in the US, the RETeval device will identify about 75% of the population as not having VTDR with 99% accuracy. The device is simple to use, does not require pupil dilation, and has a short testing time.

show abstract

Section: Introductionmentioning

confidence: 99%

A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy

Maa

Feuer

Davis

et al. 2016

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

show abstract

“…В то же время среднее улучше-ние МКОЗ в группах лазерной терапии в этих же исследованиях составило только +0,9 и +0,7 буквы (р < 0,0001). Кроме того, помимо умень-шения ДМО, терапия афлиберцептом обеспечи-вала значимое и длительное уменьшение степе-ни выраженности ретинопатии (по шкале DRSS) у большего числа пациентов, чем в группе лазера (р < 0,0004) [7].…”

Section: клинический случай 97unclassified

Aflibercept treatment in patients with diabetic macular edema

Astakhov

Сергеевич²,

Nechiporenko

et al. 2017

Ophthalmology Reports

View full text Add to dashboard Cite

The article provides a brief description of diabetic macular edema pathogenesis highlighting the role of inflammation, along with a short review of aflibercept trials in diabetic macular edema patients. Three clinical cases of diabetic macular edema treatment with aflibercept (Eylea) intravitreal injections in treatment-naïve patients are described; therapy was performed for 1 year according to the scheme provided in the Summary of Product Characteristics.

show abstract

“…[20] However, several trials evaluating anti-VEGF treatment for DME both within the DRCR network[21] and outside the network reported reduction in DR severity with anti-VEGF treatment. [22,23]…”

Section: Proliferative Diabetic Retinopathymentioning

confidence: 99%

Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network

Baker

Jiang

Stone

2016

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Structured Abstract Purpose of Review Diabetic retinopathy (DR) and diabetic macular edema (DME) are common eye diseases leading to vision loss. The Diabetic Retinopathy Clinical Research Network (DRCRnet), a collaboration of private and academic practices supported by the National Eye Institute and the National Institute of Diabetes, Digestive and Kidney Diseases have studied diabetic eye disease for 13 years. This review will discuss the network’s findings over the last year, when some of their most important contributions were reported. Recent Findings The DRCRnet reported intravitreal bevacizumab, ranibizumab and aflibercept all improve visual acuity in DME. With baseline vision of 20/30 to 20/40, all agents had similar efficacy. With baseline vision of 20/50 or worse, aflibercept resulted in superior visual improvement. Protocol S, which compared panretinal photocoagulation to intravitreal injections of ranibizumab for proliferative diabetic retinopathy (PDR), found vision outcomes and surgery rates were not inferior in the injection group. Secondary outcomes indicate improved functional results with ranibizumab supporting injections as a possible alternative treatment for PDR. Summary The DRCRnet has helped clarify the role of various treatments for both DME and PDR, and will continue to evaluate treatments for these vision-threatening conditions.

show abstract

Intravitreal Aflibercept for Diabetic Macular Edema

Cited by 471 publications

References 27 publications

A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy

A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy

Aflibercept treatment in patients with diabetic macular edema

Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network

Contact Info

Product

Resources

About